Comments on: Forget Genentech, Roche Will Still Be No. 1 http://www.pharmalot.com/2008/08/forget-genentech-roche-will-still-be-no-1/ News, Comment and Conversation Fri, 19 Mar 2010 19:15:40 +0000 http://wordpress.org/?v=2.6.2 By: Clark Kent http://www.pharmalot.com/2008/08/forget-genentech-roche-will-still-be-no-1/#comment-368861 Clark Kent Thu, 07 Aug 2008 14:20:37 +0000 http://www.pharmalot.com/?p=15005#comment-368861 That list is ridiculous. Pfizer will remain #1 by buying up as many companies as it needs to stay #1. That list is ridiculous. Pfizer will remain #1 by buying up as many companies as it needs to stay #1.

]]> By: Jeffrey Clark, CEO of Beaker.com - The Online Community for Life Sciences Professionals http://www.pharmalot.com/2008/08/forget-genentech-roche-will-still-be-no-1/#comment-368826 Jeffrey Clark, CEO of Beaker.com - The Online Community for Life Sciences Professionals Wed, 06 Aug 2008 23:28:58 +0000 http://www.pharmalot.com/?p=15005#comment-368826 If you look at HOW they calculated this table, their logic is ridiculously flawed. And, although I don't completely disagree with their Top 10, I think its not quite bulletproof. We all have been trained not to look too far down the road for predictable outcomes in drug research, approval and commercial longevity. 2014 might as well be 2041 for the sake of this report. Just consider a similar list for biotechnology companies not too many years back with Amgen, Genentech, Chiron & Immunex leading the list. 75% of those "industry stalwarts" are likely to be gone before the beginning of next year, absorbed into much larger entities. And who would have predicted the rapid emergence of companies like Gilead & Celgene. Five years ago, neither was even on the map. Fun to debate, but not of much use in reality, in my opinion. If you look at HOW they calculated this table, their logic is ridiculously flawed. And, although I don’t completely disagree with their Top 10, I think its not quite bulletproof.

We all have been trained not to look too far down the road for predictable outcomes in drug research, approval and commercial longevity. 2014 might as well be 2041 for the sake of this report.

Just consider a similar list for biotechnology companies not too many years back with Amgen, Genentech, Chiron & Immunex leading the list. 75% of those “industry stalwarts” are likely to be gone before the beginning of next year, absorbed into much larger entities. And who would have predicted the rapid emergence of companies like Gilead & Celgene. Five years ago, neither was even on the map.

Fun to debate, but not of much use in reality, in my opinion.

]]>